Where can I learn more about this trial?
You can find more information about this trial on the websites listed below.
When a full report of the trial results is available, it can also be found here.
X www.clinicaltrials.gov. Once you are on the website, type “NCT03298451”
into the “Other terms” search box and click “Search”.
X www.clinicaltrialsregister.eu. Once you are on the website, click “Home
and Search”, then type “2016-005126-11” in the search box and click
“Search”.
X www.AstraZenecaClinicalTrials.com. Once you are on the website, type
“D419CC00002” into the search box and click “Find a Study”.
Full Trial Title: A Randomized, Open-label, Multi-center Phase III Study
of Durvalumab and Tremelimumab as First-line Treatment in Patients with
Advanced Hepatocellular Carcinoma (HIMALAYA)
AstraZeneca Protocol Number: D419CC00002
National Clinical Trials Number: NCT03298451
EudraCT Number: 2016-005126-11
AstraZeneca AB sponsored this trial and has its headquarters in Södertälje,
Sweden.
The phone number for the AstraZeneca Information Center is +1-877-240-9479.
Thank you
Clinical trial participants belong to a large community of people who take
part in clinical research around the world. They help researchers answer
important health questions and find medical treatments for patients.
The Center for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organization
focused on educating and informing the public about clinical research participation. CISCRP is not involved
in recruiting participants for clinical studies, nor is it involved in conducting clinical studies.
CISCRP | One Liberty Square, Suite 1100 • Boston, MA 02109 | 1-877-MED-HERO | www.ciscrp.org
Version 1.0 2022_08_09
20 | Clinical Trial Results